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fungi, yet less toxic than amphotericin B. In this study, 
the effects of combining voriconazole (VOR) with 
amphotericin B (AM), Abelcet (AB), 5fluorocytosine 
(5FC), fluconazole (FLU), FK463, and MK0991 were 
investigated. 
Methods: The checkerboard combination test method 
was used to determine the synergistic, additive, in- 
different, or antagonistic interactions effect on minimum 
inhibitory concentration (MIC) values. Two antifungal 
agents are serially diluted in a desired medium to pro- 
duce 11 concentrations of the drugs under investigation. 
The range is chosen to include achievable serum levels 
of the drugs. The two antifungals are then combined into 
wells of a microtiter plate so that the concentration of 
one drug increases as that of the other also increases. 
Two rows consisting of serial dilutions of each individual 
drug are included for comparison. Yeast isolates tested 
include 3 strains each of Candida albicans, Candida 
glabrata, Candida krusei, Candida parapsibsis, Candida 
tropicalis, and Cryptococcus neoformans. Both fluco- 
nazole-susceptible and resistant strains were included. 
Results: All of the isolates tested were susceptible to 
VOR, AB, and AM. All Candida species were suscep- 
tible to MK and FK, while all Cryptococcus strains were 
resistant to these two antifungals. Susceptibility to 5-FC 
and FLU varied. Our data shows that VOR/MK 
combinations were 33% additive and 67% indifferent. 
VOR/FK combinations were 11% synergistic, 11% 
additive, and 78% indifferent. VOR/FLU combinations 
were 39% additive and 61% indifferent. VORAB com- 
binations were 22% additive and 72% indifferent.VOR/ 
AM combinations were 22% additive and 78% in- 
different. Finally, VOR/S-FC combinations were 11% 
additive and 89% indifferent. Importantly, no antag- 
onism was noted. 
Conclusion: Overall, 25.9% of all VOR combinations 
against these yeast isolates were either additive or 
synergistic, while 74.1% were indifferent, indicating 
minimal lowering of the individual MIC’s. Interactions 
were strain specific, suggesting that it is necessary to test 
combinations with each isolate. This study points to 
the need for expanded combination testing of VOR. 
Correlation with clinical outcome remains to be deter- 
mined. 
Antifungal activity of voriconazole alone and in two- 
drug combination with amphotericin B in a guinea pig 
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Previous in vitro studies had shown that voriconazole 
(VCZ) in two-drug combination with conventional and 
lipid formulations of amphotericin B (AMB) produced 
indifferent interaction against Aspergillus fumigatus. TO 
confirm our in vitro finding in an animal model, we 
investigated the susceptibility of A. fumigatus 73355 
(ATCC 208996) highly susceptible to VCZ (MIC 0.25 
t.J,g/mL) and AMB (MIC 0.5 ug/mL), to two-drug com- 
bination of AMB with VCZ using a guinea pig 
pulmonary aspergillosis model. Six-to-eight week old 
guinea pigs (350+50 gram) were made neutropenic by 
three successive injections of cyclophosphamide (100 
mg/kg) on day -3, -1 and 1 where day 0 was the day of 
infection. The immunosuppressed animals (14 animals/ 
group) were challenged with 1~10~ conidia/guinea pig 
by intratracheal injection. Antifungal treatment was 
initiated on day 0 (AMB 1 mg/kg/day (i.p.), VCZ 10 
mg/kg/b.i.d. (p.0.) and AMB 1 mg/kg/day + VCZ 10 
mg/kg/b.i.d.) and continued for 7 days. The effectiveness 
of the antifungal treatments with VCZ or AMB or in 
two-drug combination was evaluated by the survival and 
the fungal burden in the lungs of infected animals. The 
mean survival of animals infected but not treated 
(controls) was 3.7225 days whereas those of the AMB, 
VCZ and AMB+VCZ treated groups were 5.3k1.9, 
5.522.1 and 5.6 +1.7 days, respectively. The fungal 
burden in the lungs of infected animals treated with 
antifungal drugs was significantly lower than that 
obtained for the untreated (109733?33877 CFU/lungs) 
group. The fungal burden of the VCZ-treated (985 ?306 
CFU/lung) group was significantly lower than that 
obtained for the AMB-treated (81912 1800 CFU/lung) 
group whereas no significant difference in the fungal 
burden was obtained for the groups treated with VCZ 
alone (985+306 CFU/lung) and VCZ+AMB (8135298 
CFU/lung). We found no antagonism between VCZ and 
AMB. The results obtained in the guinea pig pulmonary 
aspergillosis model showed good agreement with our 
previous in vitro results suggesting indifferent interaction 
of VCZ in combination with AMB against A. fumigatus. 
Rhinocerebral zygomycosis - diagnostic dilemma 
for emergency physician: is reduction in morbidity 
and mortality possible in this rare but deadly disease? 
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Rhinocerebral zygomycosis (RCZ) or mucormycosis is a 
rare, invasive, rapidly progressive opportunistic infection 
caused by ubiquitous fungi of the order mucorales. It 
usually occurs in diabetics or immunocompromised 
patients. Disease is characterized by vascular invasion, 
thrombosis, and tissue necrosis. 
The emergency physician will typically see patients 
with RCZ in its earliest stages masquerading as a variety 
of other less serious diseases. The key markers like 
necrotic patch on hard palate, nasal septum or turbinate, 
marked facial pain, and cellulites with marked eye and 
neurological signs may present late in disease. 
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We report a case of RCZ caused by Rhizopus arrhizus 
(oryzae in an 84-year-old woman with poorly controlled 
diabetes. She presented with a right-sided facial droop 
of short origin, being generally unwell and ‘off legs’ over 
2 weeks with reduced appetite. Initial non-conclusive CT 
scans and late in disease appearance of key markers 
of RCZ were probably factors permitting mycosis to 
rapidly progress in its course. Despite an intensive anti- 
fungal therapy with AmBisome and Insulin sliding scale, 
patient rapidly succumbed within 4 days of presenting. 
Fine needle aspiration cytology has been suggested 
as a possible, less invasive, easier and equally effective 
alternative to pre op biopsy. The key to successful 
reduction in morbidity and mortality associated with 
this rapidly fatal disease is increasing awareness of the 
disease, an early diagnosis, correction of underlying 
metabolic derangement, prompt intensive antifungal 
therapy with amphotericin B and radical surgical 
debridement of the necrotic tissue. 
Successful treatment of fungal meningitis and 
arachnoiditis with IV voriconazole in chronic 
gramdomatous disease (CGD) 
Kiran Belani, Park Nicollet Clinic, Minneapolis, MN; 
William Mize, Childrens Hospitals and Clinic, 
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MD, USA 
Four year old black male with chronic granulomatous 
disease (CGD) diagnosed at 3 years and on treatment 
with Gamma Interferon and TMP/SMX presents with 
chronic bilateral pneumonia unresponsive to antibiotics. 
Bilateral lobectomy is done for Aspergillus fumigatus 
pneumonia and Rx with IV amphotericin for 4 months. 
Persistent headache lead to diagnosis of intracerebral 
hemorrhage requiring craniotomy and resection of R 
frontal mycotic aneurysm negative on fungal culture. On 
continued amphotericin therapy, 4 weeks later has 
intermittent sharp shooting pain in lower extremity and 
meningismus. Lumbar puncture reveals cerebrospinal 
fluid (CSF) polymorphonuclear pleocytosis, low glucose, 
elevated protein and negative fungal, bacterial and viral 
cultures. MRI spine has abnormal enhancement along 
the entire spinal cord and increased intensity in patchy 
areas in the conus medullaris and mid thoracic region. 
MRI brain shows meningeal enhancement and ventri- 
cular enlargement. Multiple craniotomy procedures were 
done to decompress the ventricles with ventriculostomy, 
Rickham reservoir and finally a ventriculoperitoneal 
shunt. Laminectomy and biopsy of spinal cord patchy 
lesions show inflammation with branching hyphae and 
yeast forms with negative cultures of tissue obtained. 
PCR was done. One CSF sample was positive for 
Trichosporon beiglii with multiple negative cultures. 
Steroid Rx started for increasing intracranial pressure 
(ICP), seizures and CSF protein on amphotericin and 
itraconazole Rx. Due to lack of clinical response anti- 
fungal Rx was changed to voriconazole (3mg/kg/dose 
BID X 12 weeks IV) provided by Pfizer (compassionate 
protocol). Patient is on oral voriconazole maintainence 
Rx for past 15 months with no steroids. He is seizure 
free, has a normal neurological examination with no 
adverse events during voriconazole therapy. Follow up 
MRI spine at 18 months shows no new areas of patchy 
lesion with resolution of previous abnormalities except 
for residual scarring. Serial MRI pictures during disease 
process will be displayed. 
A functional analysis of the Al&, Als6 and 
AM genes of Candida albicans 
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Background: Adherence of Candida albicans to host 
constituents, including endothelial cells and the base- 
ment membrane, is a critical early step in the patho- 
genesis of disseminated candidiasis. Recently, members 
of the C. albicans ALS (Aglutinin-Like-Sequence) 
gene family have been implicated as candidal adhesins. 
When the C. albicans ALS.5 gene is expressed in the 
normally non-adherent Saccharomyces cerevisiae, it 
renders this organism adherent to host constituents such 
as fibronectin. Two other members of the ALS gene 
family (ALS6 and ALS7) share considerable homology 
with AL%, but their function remains unknown. 
Purpose: To clone the C. albicans ALS6 and ALS7 gene 
and determine the role of their gene products in both 
adherence to host constituents and virulence in the 
mouse model of disseminated candidiasis. 
Methods: The coding sequence of ALSS, ALS6 and 
ALS7 were cloned using high fidelity PCR, placed under 
the control of the constitutive ADHl promotor and 
expressed in S. cerevisiae. Adherence of these strains to 
fibronectin was then tested using a magnetic bead assay. 
Using a PCR based disruption strategy, homozygous C. 
albicans null mutants of AL,!% and ALS7 were 
constructed, and the virulence of these strains was tested 
in the mouse model of disseminated candidiasis. 
Results: In contrast to AL%, heterologous expression 
of ALS6 and ALS7 in S. cerevisiae did not enhance 
adherence to fibronectin-coated beads. To further 
localize the area responsible for mediating binding to 
fibronectin, we constructed chimeric genes consisting of 
the N-terminal region of ALSS fused to the C-terminus 
of ALS6 (5N6C) and the ALS6 N-terminus fused to the 
ALSS C-terminus (6N5C). Expression of these con- 
structs in S cerevisiae resulted in enhanced adherence 
to fibronectin only in the strain expressing 5N6C. 
Consistent with these results, C. albicans ALS6 and 
ALS7 null mutants demonstrated normal virulence in 
the mouse model of disseminated candidiasis. 
